Metrion Biosciences hosted an on-demand webinar featuring Dr David Bulmer and Dr Eddy Stevens discussing the science behind Nav1.9 and pain drug discovery.

Metrion is a specialist preclinical drug discovery CRO with deep expertise in ion channel screening, including high-throughput assays. We also offer translational cardiac safety studies and neuroscience assays using DRG and other primary neurons. Our customers value the high-quality data, scientific insight, and collaborative approach that enable us to interpret results, provide tailored recommendations, and act as an extension of their research team. Metrion’s leadership team brings over 125 years of combined drug discovery experience, with 100 years focused on ion channels. This expertise, cited in around 150 publications, underpins our reputation for delivering world-class screening and discovery services. Our senior scientists and executives draw on backgrounds in pharmaceutical R&D, biotech, and CRO operations to shape strategy, drive innovation, and ensure quality outcomes for our partners.